Pfizer Stock Price, News & Analysis

ViiV Healthcare (majority owned by GSK; Pfizer ticker PFE is a shareholder) will present >60 abstracts at EACS (Oct 15-18, 2025) and IDWeek (Oct 19-22, 2025). Key highlights include initial phase I CLARITY data comparing single-dose cabotegravir long-acting (CAB LA) and lenacapavir (LEN) injections (63 HIV-negative adults), a meta-analysis of 26 studies >7,000 people on CAB+RPV LA, 96-week PASO DOBLE results showing virological outcomes for DTG/3TC vs BIC/FTC/TAF, four-year OPERA cohort data on CAB+RPV LA persistence, and phase IIb EMBRACE safety/tolerability data for the N6LS antibody with CAB LA.

Astellas Pharma will present ten abstracts at the European Society for Medical Oncology (ESMO) congress from October 17-21, 2025. The presentations include significant data from their oncology portfolio, highlighted by the EV-303 trial (KEYNOTE-905) results in muscle-invasive bladder cancer, which earned a prestigious Presidential Symposium slot.

Key presentations include final survival data for XTANDI in non-metastatic hormone-sensitive prostate cancer, long-term follow-up data from EV-302 examining enfortumab vedotin with pembrolizumab in urothelial cancer, and first clinical data for their investigational CLDN18.2-targeted bispecific T cell engager ASP2138 in solid tumors.

Pfizer (NYSE:PFE) has announced a groundbreaking agreement with the U.S. government to reduce prescription drug costs for American patients while maintaining the country's leadership in biopharmaceutical innovation. The agreement includes implementing price parity with other developed nations and participating in TrumpRx.gov, a direct purchasing platform offering discounts up to 85% on medicines.

The deal provides Pfizer with a three-year tariff grace period for products under Section 232 investigation, contingent on increased U.S. manufacturing investment. The company commits to investing an additional $70 billion in U.S. research, development, and capital projects, building upon its $83 billion investment from 2018-2024.

Pfizer (NYSE:PFE) faces a critical hearing on September 29, 2025, in a multidistrict litigation regarding its contraceptive injection Depo-Provera. The litigation, which has grown to over 1,300 lawsuits, concerns women who developed intracranial meningiomas after using the drug.

Multiple studies have confirmed increased risks, including a March 2024 study showing users were 5.6 times more likely to develop meningiomas after one year of use. A recent September 2025 JAMA Neurology study revealed a 2.43-fold increased risk for long-term users. The drug affects an estimated 74 million women globally.

The hearing will address Pfizer's pre-emption defense, where the company argues it cannot be sued for failure to warn under state law due to FDA regulations. Levin Papantonio, which has secured over $80 billion in verdicts and settlements, represents plaintiffs in this case.

Pfizer (NYSE:PFE) will showcase its oncology portfolio at the ESMO Congress 2025 in Berlin, featuring over 45 abstracts, including 5 late-breaking presentations and recognition in the Presidential Symposium.

Key highlights include the Phase 3 EV-303 trial results for PADCEV® plus KEYTRUDA® in muscle-invasive bladder cancer, final survival data from the Phase 3 EMBARK trial evaluating XTANDI® in prostate cancer, and updated survival data from the Phase 2 PHAROS study of BRAFTOVI® plus MEKTOVI® in BRAF V600E-mutant metastatic NSCLC.

The presentations span multiple cancer types, including genitourinary, thoracic, breast, and gastrointestinal cancers, demonstrating Pfizer's commitment to advancing cancer treatment standards through innovative medicines and earlier interventions.

Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for November 4, 2025, at 10:00 a.m. EST. The call will discuss Pfizer's Third Quarter 2025 Performance Report, which will be released that morning.

Investors and the public can access the webcast through www.pfizer.com/investors. Alternative access is available via phone at 800-456-4352 (US/Canada) or 785-424-1086 (International) using passcode "90164". The webcast replay and transcript will be available on Pfizer's website within 24 hours after the call and will remain accessible for at least 90 days.

Pfizer (NYSE:PFE) has announced a definitive agreement to acquire Metsera (NASDAQ:MTSR) in a deal valued at $47.50 per share in cash, representing an enterprise value of $4.9 billion. The deal includes a CVR worth up to $22.50 per share tied to clinical and regulatory milestones.

The acquisition brings Pfizer four clinical-stage incretin and amylin programs targeting obesity and cardiometabolic diseases. Key assets include MET-097i, a weekly and monthly injectable GLP-1 receptor agonist in Phase 2, and MET-233i, a monthly amylin analog in Phase 1, along with two oral GLP-1 RA candidates.

The transaction is expected to close in Q4 2025, subject to regulatory approvals and Metsera shareholder approval. This strategic move positions Pfizer in the growing obesity therapeutic area, which is associated with over 200 health conditions.

Pfizer (NYSE:PFE) and BioNTech have announced positive topline results from their Phase 3 clinical trial of the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula. The study involved 100 participants, including adults aged 65+ and those 18-64 with risk conditions for severe COVID-19.

The trial demonstrated that 14 days post-vaccination, participants showed at least a 4-fold increase in LP.8.1-neutralizing antibody titers compared to pre-vaccination levels. The safety profile remained consistent with previous studies, with no new safety concerns identified.

These findings support the recent FDA approval of the LP.8.1-adapted COVID-19 vaccine and reinforce its potential effectiveness against multiple circulating SARS-CoV-2 sublineages.

Pfizer (NYSE:PFE) and Astellas Pharma announced positive Phase 3 trial results for PADCEV plus KEYTRUDA in treating muscle-invasive bladder cancer (MIBC). The EV-303 study demonstrated that the combination therapy, when used before and after surgery, achieved statistically significant improvements in both event-free survival and overall survival compared to surgery alone in cisplatin-ineligible patients.

The groundbreaking results represent the first significant treatment advance in decades for MIBC patients who cannot receive cisplatin treatment. The combination therapy also met its secondary endpoint of pathologic complete response rate. The safety profile remained consistent with known profiles of each treatment.